Advertisement
Canada markets close in 3 hours 37 minutes

  • S&P/TSX

    22,390.42
    +131.26 (+0.59%)
     

  • S&P 500

    5,202.80
    +15.13 (+0.29%)
     

  • DOW

    39,221.84
    +165.45 (+0.42%)
     

  • CAD/USD

    0.7307
    +0.0019 (+0.26%)
     

  • CRUDE OIL

    79.22
    +0.23 (+0.29%)
     

  • Bitcoin CAD

    85,483.73
    +249.34 (+0.29%)
     

  • CMC Crypto 200

    1,342.17
    +42.07 (+3.24%)
     

  • GOLD FUTURES

    2,337.70
    +15.40 (+0.66%)
     

  • RUSSELL 2000

    2,065.65
    +10.52 (+0.51%)
     

  • 10-Yr Bond

    4.4870
    -0.0050 (-0.11%)
     

  • NASDAQ

    16,334.84
    +32.08 (+0.20%)
     

  • VOLATILITY

    13.14
    +0.14 (+1.08%)
     

  • FTSE

    8,381.35
    +27.30 (+0.33%)
     

  • NIKKEI 225

    38,073.98
    -128.39 (-0.34%)
     

  • CAD/EUR

    0.6778
    +0.0002 (+0.03%)
     
MARKETS LIVE BLOG:

STOCKS RISE AS DOW EYES EXTENDING 6-DAY WIN STREAK

U.S. jobless claims hit highest level since August 2023

Will La Jolla (LJPC) Continue to Surge Higher?

Zacks Equity Research

As of late, it has definitely been a great time to be an investor in La Jolla Pharmaceutical Co. (LJPC). The stock has moved higher by 37.2% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path.

We certainly think that this might be the case, particularly if you consider LJPC’s recent earnings estimate revision activity. From this look, the company’s future is quite favorable; as LJPC has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn’t the top for the in-focus company.




LA JOLLA PHARMACEUTICAL CO (LJPC): Free Stock Analysis Report


Zacks Investment Research